Aclaris Therapeutics Inc

NASDAQ: ACRS
$1.19
+$0.02 (+1.7%)
Closing price April 25, 2024
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.

Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More
Tuesday’s top analyst upgrades and downgrades included Campbell Soup, Exact Sciences, Exelixis, Pool, Spirit Airlines and ZTO Express.
Chris Lange
Published:

BP, Conagra, Mattel, Pepsi, UnitedHealth and More Wednesday Afternoon Analyst Calls
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including BP, Conagra Brands, Mattel, Norwegian Cruise Line, PepsiCo and UnitedHealth.
Chris Lange
Published:
Last Updated:

Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?
Aclaris shares more than doubled to start out the week after the company announced positive results from its mid-stage rheumatoid arthritis study.
Chris Lange
Published:
Last Updated: